Related Experiment Video
Updated: Nov 24, 2025
Detection of MicroRNAs in Microglia by Real-time PCR in Normal CNS and During Neuroinflammation
Published on: July 23, 2012
Quantitative polymerase Chain reaction profiling of microRNAs in peripheral lymph-monocytes from MGUS subjects
Angela Avenoso1, Salvatore Campo1, Michele Scuruchi2
1Department of Biomedical and Dental Sciences and Morphofunctional Images, Policlinico Universitario, University of Messina, 98125, Messina, Italy.
Abstract:
Monoclonal gammopathy of undetermined significance (MGUS) is a pre-malignant abnormality of plasma cells, with increased serum levels of immunoglobulins. Patients with MGUS may evolve to multiple myeloma through a multistep process including deregulated gene expression. microRNAs are small non-coding RNA molecules involved in post-transcriptional regulation of crucial biological processes, such as morphogenesis, cell differentiation, apoptosis, and cancer. This study aimed to evaluate microRNA expression on peripheral lymph-monocytes from MGUS subjects compared with healthy controls using qPCR arrays. Blood samples were collected by venipuncture from fifteen, newly diagnosed MGUS patients and fifteen healthy subjects. A further group (validation group) of six newly diagnosed MGUS patients and five healthy control were enrolled for the validation of miRNAs and their mRNAs target. The study was conducted performing miProfile miRNA qPCR arrays, followed by validation of miRNAs and related mRNA targets through RT-qPCR. The functional interaction between microRNAs and target gene were obtained by Ingenuity Pathways Analysis (IPA). IPA network analysis identified only molecules and relationships experimentally observed in peripheral lymphomonocytes. The following miRNAs :133a-3p, 16-5p, 291-3p, 23a-3p, 205-5p, 17-5p, 7a-5p, 221-3p, 30c-5p, 126a-3p,155-5p, let-7a-5p and 26a-5p, involved in the regulation of genes with a role in lymphocyte homeostasis, cell proliferation, apoptosis, and multiple myeloma (MM) progression, were differently expressed in MGUS with respect to healthy subjects. This miRNA signature and its relative targets could be considered for the formulation of new therapeutic strategies in the prophylaxis or treatment of monoclonal gammopathies.
Insights
Monoclonal gammopathy of undetermined significance (MGUS) involves abnormal plasma cells and can progress to multiple myeloma. This study identified specific microRNA signatures in MGUS patients, offering potential targets for new therapies.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Monoclonal gammopathy of undetermined significance (MGUS) is a pre-malignant condition of plasma cells.
- MGUS can progress to multiple myeloma through genetic alterations.
- MicroRNAs regulate gene expression and are implicated in various biological processes, including cancer.
Purpose of the Study:
- To investigate microRNA expression differences in peripheral blood lymph-monocytes between MGUS patients and healthy controls.
- To identify a potential microRNA signature associated with MGUS.
- To explore the therapeutic implications of these microRNA findings.
Main Methods:
- Quantitative Polymerase Chain Reaction (qPCR) arrays were used to profile microRNA expression.
- Peripheral blood samples were collected from newly diagnosed MGUS patients and healthy subjects.
- Ingenuity Pathway Analysis (IPA) was employed to analyze functional interactions between microRNAs and their target genes.
Main Results:
- A distinct set of microRNAs (e.g., miR-133a-3p, miR-16-5p, miR-29a-3p) showed differential expression in MGUS patients compared to healthy controls.
- These differentially expressed microRNAs are involved in regulating genes crucial for lymphocyte homeostasis, cell proliferation, and apoptosis.
- The identified microRNA signature and its targets are linked to multiple myeloma progression.
Conclusions:
- The study identified a specific microRNA signature in MGUS patients.
- This signature may serve as a biomarker for disease progression.
- These findings could inform the development of novel therapeutic strategies for monoclonal gammopathies.
